riskAllele	pValue	pValueAnnotation	riskFrequency	orValue	beta	ci	mappedGenes	traitName	efoTraits	bgTraits	accessionId	locations	pubmedId	author
rs527430-G	4.00E-07	(Citalopram+Buspirone, General side effects)	0.39	-	-	-	FOXD2,RPL21P24	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced side effect,response to citalopram,response to buspirone,response to antidepressant	-	GCST001308	790886:49:00	22041458	Clark SL
rs17766217-A	3.00E-07	(Citalopram+Buspirone, General side effects)	0.01	-	-	-	CASC8	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced side effect,response to citalopram,response to buspirone,response to antidepressant	-	GCST001308	2124878:52:00	22041458	Clark SL
rs16861531-G	7.00E-07	(Citalopram+Buspirone, Dizziness)	0.03	-	-	-	LINC00276	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	237634:08:00	22041458	Clark SL
rs6795349-G	2.00E-06	(Citalopram+Buspirone, Dizziness)	0.03	-	-	-	CHL1-AS2	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	2182:54:00	22041458	Clark SL
rs491376-C	2.00E-06	(Citalopram+Buspirone, Dizziness)	0.01	-	-	-	U6	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	218589:38:00	22041458	Clark SL
rs573332-G	1.00E-06	(Citalopram+Buspirone, Dizziness)	0.11	-	-	-	U6	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	218685:51:00	22041458	Clark SL
rs2163287-A	3.00E-06	(Citalopram+Buspirone, Dizziness)	0.02	-	-	-	ZDHHC14	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	2627010:11:00	22041458	Clark SL
rs7015622-C	1.00E-06	(Citalopram+Buspirone, Dizziness)	0.01	-	-	-	-	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	1383200:59:00	22041458	Clark SL
rs10988449-T	3.00E-06	(Citalopram+Buspirone, Dizziness)	0.17	-	-	-	NTMT1,LINC00963	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	2160143:41:00	22041458	Clark SL
rs8039808-A	5.00E-07	(Citalopram+Buspirone, Dizziness)	0.06	-	-	-	DTWD1	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	827475:49:00	22041458	Clark SL
rs2034588-G	2.00E-06	(Citalopram+Buspirone, Dizziness)	0.02	-	-	-	LINC02152	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	138004:45:00	22041458	Clark SL
rs12157904-G	2.00E-06	(Citalopram+Buspirone, Dizziness)	0.07	-	-	-	LGALS2,GGA1	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	626455:25:00	22041458	Clark SL
rs16990008-C	2.00E-06	(Citalopram+Buspirone, Dizziness)	0.02	-	-	-	DMD	Response to anti-depressant treatment in major depressive disorder	response to citalopram,antidepressant-induced dizziness,response to buspirone,response to antidepressant	-	GCST001308	X:31997259	22041458	Clark SL
rs10517287-T	2.00E-07	(Citalopram+Bupropion, Vision/hearing-related side effects)	0.11	-	-	-	-	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced visual impairment,response to bupropion,response to citalopram,response to antidepressant	-	GCST001308	560388:40:00	22041458	Clark SL
rs17647114-T	4.00E-07	(Citalopram+Bupropion, Vision/hearing-related side effects)	0.03	-	-	-	AGBL1	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced visual impairment,response to bupropion,response to citalopram,response to antidepressant	-	GCST001308	1448240:14:00	22041458	Clark SL
rs2291477-C	3.00E-08	(Hispanic or Latino)	0.884	-	9.31 unit increase	[6.04-12.58]	TGFBR3	QT interval (tricyclic/tetracyclic antidepressant use interaction)	response to tetracyclic antidepressant,QT interval,response to tricyclic antidepressant	-	GCST004010	1528547:18:00	28039329	Noordam R
rs6737205-A	8.00E-09	(EA)	0.94	-	56.3 unit increase	[37.29-75.31]	BABAM2	RR interval (tricyclic/tetracyclic antidepressant use interaction)	RR interval,response to tetracyclic antidepressant,response to tricyclic antidepressant	-	GCST004011	468442:46:00	28039329	Noordam R
rs9830388-A	2.00E-08	(EA)	0.51	-	25.2 unit increase	[16.38-34.02]	UBE2E2	RR interval (tricyclic/tetracyclic antidepressant use interaction)	RR interval,response to tetracyclic antidepressant,response to tricyclic antidepressant	-	GCST004011	391970:36:00	28039329	Noordam R
rs11867129-T	3.00E-07	(EA)	0.09	-	35.7 unit increase	[22.18-49.22]	ABCA3	RR interval (tricyclic/tetracyclic antidepressant use interaction)	RR interval,response to tetracyclic antidepressant,response to tricyclic antidepressant	-	GCST004011	38604:07:00	28039329	Noordam R
rs111365677-?	1.00E-07	-	NR	17.54386	-	[4.33-71.43]	LINC01708	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	1657727:18:00	27622933	Li QS
rs142484554-?	3.00E-07	-	NR	1.459854	-	[1.26-1.69]	SPSB4	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	2350993:54:00	27622933	Li QS
rs188843168-?	4.00E-07	-	NR	449.83	-	[5.402-Inf]	ATP5MK	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	1723179:44:00	27622933	Li QS
rs6546604-?	5.00E-07	-	NR	1.2787724	-	[1.16-1.41]	BRD7P6,TGFA	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	1173596:35:00	27622933	Li QS
rs34177316-?	6.00E-07	-	NR	1.355	-	[1.203-1.528]	APBB2	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	683092:03:00	27622933	Li QS
rs201921722-?	7.00E-07	-	NR	1.2642225	-	[1.15-1.39]	SCN3B,ZNF202	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	2061344:20:00	27622933	Li QS
rs80278479-?	8.00E-07	-	NR	14.492754	-	[3.88-55.56]	TFAP2D	Response to citalopram or escitalopram in depression	response to escitalopram,response to citalopram	unipolar depression,mood disorder	GCST003802	845980:26:00	27622933	Li QS
rs13432159-G	9.00E-08	(Sertraline, General side effects)	0.08	-	-	-	LINC01812	Response to anti-depressant treatment in major depressive disorder	response to sertraline,antidepressant-induced side effect,response to antidepressant	-	GCST001308	1129114:35:00	22041458	Clark SL
rs6724422-T	4.00E-07	(Sertraline, General side effects)	0.06	-	-	-	LINC01812	Response to anti-depressant treatment in major depressive disorder	response to sertraline,antidepressant-induced side effect,response to antidepressant	-	GCST001308	1129162:56:00	22041458	Clark SL
rs6063349-?	7.00E-07	-	NR	1.183432	-	[1.11-1.27]	CSE1L	Non-response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003810	817775:45:00	27622933	Li QS
rs142641502-?	8.00E-07	-	NR	4.565	-	[2.155-9.671]	CSTF3	Non-response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003810	551842:01:00	27622933	Li QS
rs201569130-?	9.00E-07	-	NR	3.009	-	[1.785-5.073]	FOXF2	Non-response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003810	23387:56:00	27622933	Li QS
rs1548076-?	1.00E-06	-	NR	2.4937656	-	[1.63-3.82]	DRAIC	Non-response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003810	1165586:24:00	27622933	Li QS
rs182377406-?	1.00E-06	-	NR	5.773	-	[3.250-10.254]	GPR152,CORO1B	Non-response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003810	1124167:18:00	27622933	Li QS
rs143934587-?	7.00E-07	-	NR	6.711409	-	[3.61-12.5]	SLC24A3	Response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003811	319450:06:00	27622933	Li QS
rs74860738-?	3.00E-07	-	NR	1.2870014	-	[1.17-1.41]		Response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003811	1344539:03:00	27622933	Li QS
rs189864513-?	8.00E-07	-	NR	12.345678	-	[5.65-27.03]	LINC01618	Response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003811	879460:30:00	27622933	Li QS
rs11924809-?	1.00E-06	-	NR	1.215	-	[1.122-1.316]	DGKG	Response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003811	3105897:16:00	27622933	Li QS
rs117375960-?	2.00E-06	-	NR	142.85713	-	[2.9-âˆž]	NT5C2	Response to citalopram or escitalopram and depression	unipolar depression,response to escitalopram,response to citalopram,mood disorder	-	GCST003811	1719375:07:00	27622933	Li QS
rs2973692-C	2.00E-07	-	NR	-	2.77E-10 unit increase	[-8.28643-8.28643]	COL23A1	HDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	response to escitalopram,response to citalopram,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012320	2972112:52:00	33824429	Fjukstad KK
rs2961701-G	6.00E-07	-	NR	-	6.29E-18 unit increase	[-15.55295-15.55295]	SPRY4,NDFIP1	HDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	response to escitalopram,response to citalopram,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012320	2370358:18:00	33824429	Fjukstad KK
rs117122954-C	9.00E-09	-	NR	-	15.6213 unit decrease	[10.6-20.65]	CGNL1	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram		GCST012319	957474:07:00	33824429	Fjukstad KK
rs7015376-T	3.00E-07	-	NR	-	12.0039 unit decrease	[7.6-16.4]	GRHL2	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1692577:56:00	33824429	Fjukstad KK
rs9854831-A	5.00E-07	-	NR	-	8.73719 unit decrease	[6.44-11.03]	LINC02069	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	3079442:49:00	33824429	Fjukstad KK
rs7017107-G	9.00E-07	-	NR	-	2.90073 unit increase	[1.8-4]	-	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	358944:19:00	33824429	Fjukstad KK
rs73522151-C	1.00E-06	-	NR	-	19.4674 unit decrease	[12-26.94]	RBFOX1	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	100471:54:00	33824429	Fjukstad KK
rs71582886-A	1.00E-06	-	NR	-	12.2189 unit decrease	[7.87-16.57]	RELN	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1729168:25:00	33824429	Fjukstad KK
rs58974557-G	2.00E-06	-	NR	-	15.489 unit decrease	[9.44-21.54]	DPP6	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	2577421:24:00	33824429	Fjukstad KK
rs118129203-C	4.00E-06	-	NR	-	18.2848 unit decrease	[10.79-25.78]	Y_RNA,RNU6-1286P	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	2022704:47:00	33824429	Fjukstad KK
rs12727338-A	5.00E-06	-	NR	-	2.39409 unit increase	[1.42-3.37]	ACTRT2	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	49516:05:00	33824429	Fjukstad KK
rs77812015-C	6.00E-06	-	NR	-	14.4129 unit decrease	[8.42-20.4]	PLGRKT,CD274	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	90736:56:00	33824429	Fjukstad KK
rs76714130-G	6.00E-06	-	NR	-	11.1853 unit decrease	[6.53-15.84]	CHST11	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1744028:09:00	33824429	Fjukstad KK
rs962987-T	6.00E-06	-	NR	-	2.06139 unit increase	[1.2-2.92]	TRIML2,ZFP42	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	3133850:19:00	33824429	Fjukstad KK
rs72701151-G	7.00E-06	-	NR	-	19.5183 unit decrease	[11.33-27.71]	RFX3-AS1	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	61607:51:00	33824429	Fjukstad KK
rs72927277-A	7.00E-06	-	NR	-	11.7895 unit decrease	[7.54-16.04]	MTCYBP36	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1573390:47:00	33824429	Fjukstad KK
rs116869376?-T	8.00E-06	-	NR	-	13.547 unit decrease	[7.82-19.27]	SNX13	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	297873:21:00	33824429	Fjukstad KK
rs75608892-C	8.00E-06	-	NR	-	19.0116 unit decrease	[10.97-27.06]	RIMS1	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1207217:41:00	33824429	Fjukstad KK
rs6018666-C	9.00E-06	-	NR	-	2.09401 unit increase	[1.2-2.99]	SULF2	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	795799:11:00	33824429	Fjukstad KK
rs116203827-G	1.00E-05	-	NR	-	13.6681 unit decrease	[7.82-19.52]	ZFHX3	LDL levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to escitalopram,response to citalopram	schizophrenia,bipolar disorder	GCST012319	1229833:52:00	33824429	Fjukstad KK
rs73522151-C	3.00E-07	-	NR	-	22.1596 unit decrease	[14.03-30.29]	RBFOX1	Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012318	100471:54:00	33824429	Fjukstad KK
rs71478642-C	4.00E-06	-	NR	-	17.0997 unit decrease	[10.13-24.07]	ALDH1A2	Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012318	965134:51:00	33824429	Fjukstad KK
rs75608892-C	8.00E-06	-	NR	-	20.9468 unit decrease	[12.07-29.82]	RIMS1	Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012318	1207217:41:00	33824429	Fjukstad KK
rs17665285-A	1.00E-05	-	NR	-	2.68114 unit decrease	[1.53-3.83]	SLIT3	Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012318	2812093:24:00	33824429	Fjukstad KK
rs72828888-G	1.00E-05	-	NR	-	2.97739 unit increase	[1.7-4.25]	ARHGAP25	Total cholesterol levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012318	1145984:33:00	33824429	Fjukstad KK
rs111851914-A	3.00E-07	-	NR	-	12.05 unit increase	[7.48-16.62]	CLVS2	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	2049443:52:00	33824429	Fjukstad KK
rs1578568-A	1.00E-06	-	NR	-	11.71 unit increase	[7.11-16.31]	PDYN-AS1,RPL7P2	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	34036:17:00	33824429	Fjukstad KK
rs12321461-C	1.00E-06	-	NR	-	3.26515 unit decrease	[2-4.53]	BRWD1P2	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1497879:29:00	33824429	Fjukstad KK
rs72841380-A	1.00E-06	-	NR	-	11.0145 unit increase	[6.72-15.3]	CNTNAP5	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	2076787:06:00	33824429	Fjukstad KK
rs4949169-A	2.00E-06	-	NR	-	1.94624 unit increase	[1.18-2.71]	LINC02782	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	85045:07:00	33824429	Fjukstad KK
rs806447-G	3.00E-06	-	NR	-	2.11371 unit increase	[1.27-2.95]	SPACA1,CNR1	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1468190:32:00	33824429	Fjukstad KK
rs75502766-C	4.00E-06	-	NR	-	-	[NR]	-	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1762245:26:00	33824429	Fjukstad KK
rs150979961-T	4.00E-06	-	NR	-	8.98186 unit increase	[5.31-12.66]	Metazoa_SRP,VTCN1	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1953641:57:00	33824429	Fjukstad KK
22:28173030-A	4.00E-06	-	NR	-	1.93734 unit increase	[1.14-2.73]	-	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	-	33824429	Fjukstad KK
rs72811286-G	5.00E-06	-	NR	-	12.0554 unit increase	[7.08-17.04]	UNC5A	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	2947082:10:00	33824429	Fjukstad KK
rs117746782-C	7.00E-06	-	NR	-	12.199 unit increase	[7.08-17.31]	ABCA1,CCDC171	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	268339:19:00	33824429	Fjukstad KK
rs546982-A	8.00E-06	-	NR	-	2.08156 unit decrease	[1.2-2.96]	FANCG,PIGO	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	584761:29:00	33824429	Fjukstad KK
rs2185431-C	8.00E-06	-	NR	-	10.02 unit increase	[5.6-14.44]	-	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1707547:38:00	33824429	Fjukstad KK
rs12644930-T	8.00E-06	-	NR	-	10.67 unit increase	[6.73-14.61]	SORBS2	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	3095283:02:00	33824429	Fjukstad KK
rs112009437-A	8.00E-06	-	NR	-	-	[NR]	FGF4,DNAJB6P5	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	1162765:02:00	33824429	Fjukstad KK
rs7723088-G	9.00E-06	-	NR	-	5.15361 unit decrease	[2.95-7.35]	CNOT6	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to escitalopram,response to citalopram	bipolar disorder,schizophrenia	GCST012317	3008386:59:00	33824429	Fjukstad KK
rs2742417-T	5.00E-07	(Bupropion, Sexual side effects)	0.49	-	-	-	SACM1L	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced sexual dysfunction,response to bupropion,response to antidepressant	-	GCST001308	761502:19:00	22041458	Clark SL
rs7136572-G	3.00E-07	(Bupropion, Sexual side effects)	0.04	-	-	-	PGAM1P5	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced sexual dysfunction,response to bupropion,response to antidepressant	-	GCST001308	1592778:52:00	22041458	Clark SL
rs10857636-T	2.00E-07	(Bupropion, General side effects)	0.06	-	-	-	WDFY4	Response to anti-depressant treatment in major depressive disorder	response to bupropion,antidepressant-induced side effect,response to antidepressant	-	GCST001308	812961:05:00	22041458	Clark SL
rs17150687-C	3.00E-06	(Bupropion, Sexual side effects)	0.02	-	-	-	MAGI2	Response to anti-depressant treatment in major depressive disorder	antidepressant-induced sexual dysfunction,response to bupropion,response to antidepressant	-	GCST001308	1306906:34:00	22041458	Clark SL
rs11949289-T	2.00E-07	(Venlafaxine, Dizziness)	0.42	-	-	-	LINC02103	Response to anti-depressant treatment in major depressive disorder	response to venlafaxine,antidepressant-induced dizziness,response to antidepressant	-	GCST001308	472339:26:00	22041458	Clark SL
rs4685959-?	1.00E-06	-	NR	-	1.1 unit decrease	[NR]	-	Duloxetine response in major depressive disorder (% change in symptom score)	response to duloxetine	unipolar depression	GCST004738	94095:57:00	28696415	Maciukiewicz M
rs13147572-?	8.00E-06	-	NR	-	0.44 unit decrease	[NR]	SORBS2	Duloxetine response in major depressive disorder (% change in symptom score)	response to duloxetine	unipolar depression	GCST004738	304862:41:00	28696415	Maciukiewicz M
rs140369800-G	1.00E-05	-	NR	1.7569	-	NR	ASAP2	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	156573:40:00	33106475	Li QS
rs12630112-G	1.00E-06	-	NR	1.4352	-	NR	RNU6-217P,ROBO2	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1295265:53:00	33106475	Li QS
rs6548531-G	2.00E-06	-	NR	0.7019	-	NR	RNU6-217P	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1298455:57:00	33106475	Li QS
rs224461-T	9.00E-06	-	NR	0.8226	-	NR	HS3ST1	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	190182:20:00	33106475	Li QS
rs35533749-?	6.00E-06	-	NR	1.389	-	NR	PRDM5	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	2011690:04:00	33106475	Li QS
rs34368137-T	6.00E-06	-	NR	0.8158	-	NR	ADGRV1	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1514344:23:00	33106475	Li QS
rs72782825-T	2.00E-06	-	NR	0.6909	-	NR	-	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1687673:54:00	33106475	Li QS
rs148907117-T	7.00E-07	-	NR	3.5989	-	NR	-	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1756151:48:00	33106475	Li QS
rs117461877-T	7.00E-06	-	NR	0.4295	-	NR	KCNQ5	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1215708:41:00	33106475	Li QS
rs117755882-C	5.00E-06	-	NR	0.4515	-	NR	AGMO	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	259325:49:00	33106475	Li QS
rs55909142-T	5.00E-07	-	NR	0.8391	-	NR	HMGN1P19,ZNF619P1	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	777243:16:00	33106475	Li QS
rs6651270-G	3.00E-06	-	NR	1.2361	-	NR	CPNE3	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1442092:04:00	33106475	Li QS
rs3739288-T	6.00E-06	-	NR	1.291	-	NR	FBXO32	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	2058560:17:00	33106475	Li QS
rs2505689-T	1.00E-06	-	NR	1.2273	-	NR	VN1R53P	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	623420:13:00	33106475	Li QS
rs77330698-G	6.00E-06	-	NR	0.6787	-	NR	ABLIM1	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1909901:55:00	33106475	Li QS
rs665654-G	5.00E-06	-	NR	0.8466	-	NR	ZBTB44	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	2170500:50:00	33106475	Li QS
rs2358884-C	9.00E-06	-	NR	0.7086	-	NR	SAMD4A	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	910415:39:00	33106475	Li QS
rs199610398-?	3.00E-06	-	NR	0.4725	-	NR	AK7,PAPOLA-DT	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1608197:21:00	33106475	Li QS
rs1984528-G	3.00E-06	-	NR	0.837	-	NR	SNRPCP18,LINC02348	Response to norepinephrine-dopamine reuptake inhibitors (responders vs non-responders)	response to norepinephrine-dopamine reuptake inhibitor	-	GCST012158	1692756:31:00	33106475	Li QS
rs140297241-T	4.00E-06	-	NR	2.2041	-	NR	NFATC2	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	858056:10:00	33106475	Li QS
rs12046604-T	1.00E-05	-	NR	0.7007	-	NR	GBP6,GBP5	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1489152:53:00	33106475	Li QS
rs6689881-T	6.00E-06	-	NR	1.1853	-	NR	LGALS8,EDARADD	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	3941812:44:00	33106475	Li QS
rs144159691-T	1.00E-05	-	NR	0.3982	-	NR	KCNS3	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	303806:08:00	33106475	Li QS
rs6710522-G	5.00E-07	-	NR	0.7502	-	NR	YIPF4,BIRC6	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	538882:06:00	33106475	Li QS
rs4435504-T	5.00E-07	-	NR	1.3285	-	NR	BIRC6	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	542248:41:00	33106475	Li QS
rs11687719-G	2.00E-06	-	NR	1.182	-	NR	CRTC1P1,FTH1P6	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	877160:13:00	33106475	Li QS
rs17044107-T	9.00E-06	-	NR	1.3496	-	NR	-	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	885009:10:00	33106475	Li QS
rs71314391-G	3.00E-06	-	NR	0.5266	-	NR	IRAK2	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	170001:01:00	33106475	Li QS
rs114203670-G	8.00E-06	-	NR	1.9023	-	NR	GK5	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2369805:05:00	33106475	Li QS
rs4955665-T	2.00E-09	-	NR	1.245	-	NR	MECOM	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2827290:11:00	33106475	Li QS
rs13073066-T	8.00E-06	-	NR	1.1855	-	NR	RNU6-637P,TERC	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2829028:28:00	33106475	Li QS
rs74348612-T	4.00E-06	-	NR	1.4369	-	NR	MAEA	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	21813:24:00	33106475	Li QS
rs3936615-G	3.00E-06	-	NR	0.777	-	NR	SORCS2	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	122217:30:00	33106475	Li QS
rs185114853-T	7.00E-06	-	NR	0.2947	-	NR	GALNTL6	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2877191:52:00	33106475	Li QS
rs144768167-C	9.00E-06	-	NR	0.3227	-	NR	GALNTL6	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2878874:14:00	33106475	Li QS
rs117875254-T	2.00E-06	-	NR	0.6007	-	NR	-	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	150269:00:00	33106475	Li QS
rs186638945-T	3.00E-06	-	NR	1.7936	-	NR	CCDC71L	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1777213:16:00	33106475	Li QS
rs10104815-T	5.00E-08	-	NR	1.215	-	NR	RNU1-35P,LINC02055	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	2263290:19:00	33106475	Li QS
rs201857596-?	9.00E-06	-	NR	1.3417	-	NR	EXOSC3	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	629658:34:00	33106475	Li QS
rs78254522-T	5.00E-07	-	NR	0.569	-	NR	ANK3	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1005259:22:00	33106475	Li QS
rs481206-T	2.00E-06	-	NR	1.1922	-	NR	ARAP1,STARD10	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1213117:57:00	33106475	Li QS
rs199882651-?	9.00E-06	-	NR	0.836	-	NR	FCHSD2	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1217343:08:00	33106475	Li QS
rs940850-T	2.00E-06	-	NR	0.7505	-	NR	NTN1	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	150463:03:00	33106475	Li QS
rs372464-G	5.00E-06	-	NR	0.8232	-	NR	NFATC1	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	1325540:59:00	33106475	Li QS
rs293711-G	8.00E-06	-	NR	0.8517	-	NR	BPIFB9P	Response to serotonin-norepinephrine reuptake inhibitors (responders vs non-responders)	response to serotonin-norephinephrine reuptake inhibitor	-	GCST012159	555894:12:00	33106475	Li QS
rs1908557-T	3.00E-08	-	NR	1.348	-	[1.213-1.497]	-	Response to bupropion in depression	response to bupropion	unipolar depression,mood disorder	GCST003800	1491674:02:00	27622933	Li QS
rs77945277-?	2.00E-07	-	NR	11.111111	-	[3.83-32.26]	BAZ1A	Response to bupropion in depression	response to bupropion	unipolar depression,mood disorder	GCST003800	580696:49:00	27622933	Li QS
rs4839421-?	5.00E-07	-	NR	1.249	-	[1.146-1.362]	PROK1,CYMP	Response to bupropion in depression	response to bupropion	unipolar depression,mood disorder	GCST003800	1841323:18:00	27622933	Li QS
rs75995702-?	7.00E-07	-	NR	12.857	-	[3.496-47.288]	-	Response to bupropion in depression	response to bupropion	unipolar depression,mood disorder	GCST003800	713097:17:00	27622933	Li QS
rs34102224-?	1.00E-06	-	NR	1.354	-	[1.197-1.531]	-	Response to bupropion in depression	response to bupropion	unipolar depression,mood disorder	GCST003800	89416:26:00	27622933	Li QS
rs977145-A	7.00E-06	-	NR	-	-	-	ZRANB2-AS2,NEGR1	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004271	1191061:06:00	28437668	Jung J
rs7853333-A	4.00E-06	-	NR	-	-	-	RN7SKP114,DCAF12	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004271	567770:01:00	28437668	Jung J
rs76778048-A	8.00E-06	(CGI)	0.25	10.2	-	-	LINC02549	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004270	1137006:40:00	28437668	Jung J
rs3819595-A	4.00E-06	(HAM-A)	0.35	6.45	-	-	PCP4	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004270	665200:33:00	28437668	Jung J
rs2070419-A	5.00E-06	(CGI)	0.47	6.09	-	-	FBXW11P1,TIAM1	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004270	526032:51:00	28437668	Jung J
rs3020264-A	3.00E-06	(HAM-A)	0.48	4.7	-	-	MCPH1,MCPH1-AS1	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004273	110525:36:00	28437668	Jung J
rs10914746-G	9.00E-06	(CGI)	0.43	4.63	-	-	CSMD2	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004273	559571:44:00	28437668	Jung J
rs7984972-A	8.00E-06	(CGI)	0.57	4.17	-	-	-	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004273	523910:51:00	28437668	Jung J
rs13129231-A	6.00E-06	(CGI)	0.9	5.88	-	-	CAMK2D	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004274	1890532:45:00	28437668	Jung J
rs2236295-A	5.00E-06	(CGI)	0.52	4.14	-	-	ADO	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004274	1046762:12:00	28437668	Jung J
rs7152947-A	3.00E-06	(HAM-A)	0.89	5.88	-	-	ANGEL1	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004274	1280443:10:00	28437668	Jung J
rs8020289-G	9.00E-06	(HAM-A)	0.88	5.26	-	-	LRRC74A	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004274	1280466:57:00	28437668	Jung J
rs2307441-G	3.00E-06	(HAM-A)	0.22	14.38	-	-	POLG	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004275	1488658:15:00	28437668	Jung J
rs6712232-G	5.00E-06	(CGI)	0.22	14.28	-	-	RPS20P10,DYSF	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004275	1198400:22:00	28437668	Jung J
rs3013580-G	2.00E-06	(CGI)	0.59	6.23	-	-	LINC00364	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004275	1122171:04:00	28437668	Jung J
rs75965524-G	4.00E-06	(CGI)	0.22	14.47	-	-	AGAP1	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004275	3932026:54:00	28437668	Jung J
rs6918679-A	8.00E-07	(CGI)	0.28	11.97	-	-	-	Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	response to venlafaxine	generalized anxiety disorder	GCST004275	1247053:41:00	28437668	Jung J
rs17450029-T	3.00E-06	(Tri-Tetra/cyclic antidepressants)	0.23	-	-	-	DPH5	QT interval (drug interaction)	QT interval,response to tricyclic antidepressant	-	GCST001890	1684591:43:00	23459443	Avery CL
rs3217869-A	4.00E-06	(Tri-Tetra/cyclic antidepressants)	0.41	-	-	-	CCND2	QT interval (drug interaction)	QT interval,response to tricyclic antidepressant	-	GCST001890	71525:24:00	23459443	Avery CL
rs2708240-A	4.00E-06	(Tri-Tetra/cyclic antidepressants)	0.51	-	-	-	CNTNAP2	QT interval (drug interaction)	QT interval,response to tricyclic antidepressant	-	GCST001890	2464681:05:00	23459443	Avery CL
rs6755560-T	2.00E-06	(Tri-Tetra/cyclic antidepressants)	0.32	-	-	-	FASTKD2,CPO	QT interval (drug interaction)	QT interval,response to tricyclic antidepressant	-	GCST001890	3447552:59:00	23459443	Avery CL
rs9375225-T	6.00E-06	(Tri-Tetra/cyclic antidepressants)	0.48	-	-	-	EIF4EBP2P3	QT interval (drug interaction)	QT interval,response to tricyclic antidepressant	-	GCST001890	1635687:18:00	23459443	Avery CL
rs6889896-?	5.00E-07	(% Change in score)	NR	-	0.17 unit decrease	[NR]	LINC02240	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	2089397:26:00	25897834	Biernacka JM
rs35806662-?	6.00E-07	(% Change in score)	NR	-	0.2 unit decrease	[NR]	UPP2	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	2632233:53:00	25897834	Biernacka JM
rs73069924-?	8.00E-07	(% Change in score)	NR	-	0.44 unit decrease	[NR]	MTMR12	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	537973:47:00	25897834	Biernacka JM
rs4615376-?	1.00E-06	(% Change in score)	NR	-	0.16 unit decrease	[NR]	PHACTR1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	217853:21:00	25897834	Biernacka JM
rs2566255-?	2.00E-06	(% Change in score)	NR	-	0.26 unit increase	[NR]	OR52I2	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	76410:25:00	25897834	Biernacka JM
rs910039-?	2.00E-06	(% Change in score)	NR	-	0.13 unit increase	[NR]	CAP2	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	291767:53:00	25897834	Biernacka JM
rs17068112-?	3.00E-06	(% Change in score)	NR	-	0.26 unit increase	[NR]	REPS1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	2315489:08:00	25897834	Biernacka JM
rs7485210-?	3.00E-06	(% Change in score)	NR	-	0.14 unit increase	[NR]	LINC01257,ADGRD1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	2185917:08:00	25897834	Biernacka JM
rs74378198-?	4.00E-06	(% Change in score)	NR	-	0.43 unit decrease	[NR]	OSMR	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	647851:46:00	25897834	Biernacka JM
rs4236420-?	4.00E-06	(% Change in score)	NR	-	0.13 unit increase	[NR]	PER3P1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	160814:59:00	25897834	Biernacka JM
rs2456568-?	5.00E-08	(Response)	NR	1.36	-	[NR]	HPRT1P3	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	1565980:26:00	25897834	Biernacka JM
rs113889867-?	9.00E-07	(Response)	NR	1.96	-	[NR]	STMN2	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	1327412:25:00	25897834	Biernacka JM
rs10954808-?	1.00E-06	(Response)	NR	1.37	-	[NR]	RNA5SP261,NRG1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	527043:07:00	25897834	Biernacka JM
rs506546-?	1.00E-06	(Response)	NR	1.32	-	[NR]	CSMD2	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	566229:13:00	25897834	Biernacka JM
rs74546197-?	3.00E-06	(Response)	NR	2.17	-	[NR]	SLC26A9,PM20D1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	3431851:51:00	25897834	Biernacka JM
rs72772787-?	4.00E-06	(Response)	NR	2.34	-	[NR]	OR11L1,TRIM58	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	4130885:36:00	25897834	Biernacka JM
rs2043144-?	4.00E-06	(Response)	NR	2.63	-	[NR]	TRPM3	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	1188942:59:00	25897834	Biernacka JM
rs291028-?	5.00E-06	(Response)	NR	1.64	-	[NR]	-	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	1584557:37:00	25897834	Biernacka JM
rs7051085-?	6.00E-06	(Response)	NR	1.59	-	[NR]	PTCHD1	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	X:23356860	25897834	Biernacka JM
rs1210638-?	6.00E-06	(Response)	NR	1.33	-	[NR]	DGCR5	Response to serotonin reuptake inhibitors in major depressive disorder	response to selective serotonin reuptake inhibitor	unipolar depression	GCST002868	316589:30:00	25897834	Biernacka JM
rs17768250-?	7.00E-07	-	NR	2.3758	-	NR	ZFAT	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	2242648:31:00	29160301	Fabbri C
rs79645820-?	5.00E-06	-	NR	2.8465698	-	NR	KYNU,ARHGAP15	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	2384784:19:00	29160301	Fabbri C
rs12044299-?	4.00E-06	-	NR	2.1362956	-	NR	KAZN	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	232694:44:00	29160301	Fabbri C
rs12644500-?	5.00E-06	-	NR	1.6038493	-	NR	LINC01378	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	1959773:57:00	29160301	Fabbri C
rs7482428-?	4.00E-07	-	NR	1.4643433	-	NR	HBE1,HBG2,OR51B5	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	88697:36:00	29160301	Fabbri C
rs1102156-?	2.00E-06	-	NR	1.4518	-	NR	RN7SL150P,KCTD15	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	564150:22:00	29160301	Fabbri C
rs3935545-?	3.00E-06	-	NR	1.6929	-	NR	LINC02361,NOC4L	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	2203038:19:00	29160301	Fabbri C
rs4352485-?	2.00E-06	-	NR	1.9615	-	NR	TBC1D1	Response to SSRI (symptom remission)	response to selective serotonin reuptake inhibitor	-	GCST007060	632930:07:00	29160301	Fabbri C
rs146158788-?	6.00E-06	-	NR	0.7349	-	NR	RERE	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	1750750:58:00	33106475	Li QS
rs6704443-T	3.00E-06	-	NR	0.9026	-	NR	NTPCR	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	3882637:49:00	33106475	Li QS
rs80164876-G	8.00E-06	-	NR	1.5482	-	NR	EGFLAM	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	641074:02:00	33106475	Li QS
rs56276481-T	1.00E-05	-	NR	0.8016	-	NR	P4HA2	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	2020285:36:00	33106475	Li QS
rs1106260-T	2.00E-07	-	NR	0.8889	-	NR	C9orf62	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	2254081:08:00	33106475	Li QS
rs17769621-G	1.00E-06	-	NR	0.5889	-	NR	C10orf90	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	2113018:14:00	33106475	Li QS
rs75596821-G	6.00E-06	-	NR	0.7298	-	NR	OR52B4,SSU72P7	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	72446:37:00	33106475	Li QS
rs201766116-?	4.00E-06	-	NR	1.4873	-	NR	TEAD4,TSPAN9	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	50931:30:00	33106475	Li QS
rs4884091-G	2.00E-07	-	NR	1.1553	-	NR	OBI1-AS1	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	1306664:28:00	33106475	Li QS
rs2268972-T	9.00E-06	-	NR	1.1125	-	NR	ACTN1	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	1149311:17:00	33106475	Li QS
rs72731766-T	8.00E-06	-	NR	1.437	-	NR	SEMA6D	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	787770:21:00	33106475	Li QS
rs55905802-T	7.00E-06	-	NR	0.7148	-	NR	MAP2K1	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	1108030:39:00	33106475	Li QS
rs903975-T	8.00E-06	-	NR	1.1031	-	NR	AGBL1	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	1437607:27:00	33106475	Li QS
rs12607258-C	8.00E-06	-	NR	1.134	-	NR	OSBPL1A	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	403273:00:00	33106475	Li QS
rs11083575-G	7.00E-06	-	NR	1.129	-	NR	CYP2A7	Response to SSRI (responders vs non-responders)	response to selective serotonin reuptake inhibitor	-	GCST012160	681284:35:00	33106475	Li QS
rs80164876-?	4.00E-07	-	NR	2.09	-	[1.551-2.815]	EGFLAM	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression,mood disorder	GCST003801	641074:02:00	27622933	Li QS
rs114465512-?	5.00E-07	-	NR	12.987013	-	[3.98-43.48]	IGLV10-67,IGLVIV-66-1	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression,mood disorder	GCST003801	367486:55:00	27622933	Li QS
rs35863382-?	7.00E-07	-	NR	1.540832	-	[1.3-1.83]	PPP4R3A	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression,mood disorder	GCST003801	1524556:12:00	27622933	Li QS
rs117198528-?	9.00E-07	-	NR	1.823	-	[1.437-2.313]	SMUG1P1,ACAA2	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression,mood disorder	GCST003801	828254:28:00	27622933	Li QS
rs138472420-?	1.00E-06	-	NR	5.628	-	[2.692-11.767]	BICRA	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression,mood disorder	GCST003801	794315:05:00	27622933	Li QS
rs7785360-?	2.00E-08	-	NR	-	-	-	AUTS2	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST003118	1165746:52:00	26348319	Myung W
rs10924309-?	6.00E-06	-	NR	-	-	-	KIF26B	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST003118	4094999:40:00	26348319	Myung W
rs6978272-?	7.00E-06	-	NR	3.448276	-	[2-5.88]	EXOC4	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST006267	2223395:05:00	30034349	Lin E
rs7954376-?	4.00E-06	-	NR	3.448276	-	[2.04-5.88]	GRIN2B	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST006267	224698:21:00	30034349	Lin E
rs4810894-?	3.00E-06	-	NR	2.7	-	[1.78-4.10]	PREX1,ARFGEF2	Response to selective serotonin reuptake inhibitors in depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST006267	815294:22:00	30034349	Lin E
rs77554113-?	1.00E-06	-	NR	4.81	-	[2.54-9.13]	TSHZ3	Remission after SSRI treatment in major depression	response to selective serotonin reuptake inhibitor	unipolar depression	GCST006266	519019:34:00	30034349	Lin E
rs10784781-?	4.00E-06	-	NR	1.5360984	-	NR	RPS26P45,LINC02373	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	1157249:36:00	29160301	Fabbri C
rs1102156-?	3.00E-06	-	NR	1.4086	-	NR	RN7SL150P,KCTD15	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	564150:22:00	29160301	Fabbri C
rs11733276-?	5.00E-07	-	NR	1.61577	-	NR	LINC01378	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	1959670:43:00	29160301	Fabbri C
rs17768250-?	7.00E-07	-	NR	2.1933	-	NR	ZFAT	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	2242648:31:00	29160301	Fabbri C
rs35551581-?	4.00E-06	-	NR	1.600512	-	NR	RB1CC1,NPBWR1	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	880755:19:00	29160301	Fabbri C
rs3849106-?	3.00E-06	-	NR	1.4394	-	NR	MYO10	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	278435:06:00	29160301	Fabbri C
rs4352485-?	3.00E-06	-	NR	1.8042	-	NR	TBC1D1	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	632930:07:00	29160301	Fabbri C
rs7420310-?	4.00E-06	-	NR	1.4220706	-	NR	USP21P2,RN7SKP203	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	1272603:50:00	29160301	Fabbri C
rs74442120-?	2.00E-06	-	NR	3.9588277	-	NR	MYT1L	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	40073:42:00	29160301	Fabbri C
rs7482428-?	2.00E-07	-	NR	1.440507	-	NR	HBE1,HBG2,OR51B5	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	88697:36:00	29160301	Fabbri C
rs76756809-?	1.00E-06	-	NR	1.7205782	-	NR	-	Response to antidepressants (symptom remission)	response to antidepressant	-	GCST007061	1098638:59:00	29160301	Fabbri C
rs17382228-?	2.00E-06	-	NR	-	0.044 unit decrease	NR	SORCS2	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	129027:28:00	29160301	Fabbri C
rs6878462-?	2.00E-06	-	NR	-	0.1196 unit decrease	NR	CTNND2	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	186642:05:00	29160301	Fabbri C
rs112687359-?	5.00E-06	-	NR	-	0.068 unit decrease	NR	ADGRE3	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	244149:00:00	29160301	Fabbri C
rs59689479-?	4.00E-06	-	NR	-	0.1674 unit decrease	NR	CSGALNACT1	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	327725:00:00	29160301	Fabbri C
rs61924290-?	3.00E-06	-	NR	-	0.1183 unit decrease	NR	-	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	389816:56:00	29160301	Fabbri C
rs116692768-?	2.00E-06	-	NR	-	0.1261 unit decrease	NR	ITGA9	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	624986:11:00	29160301	Fabbri C
rs298207-?	5.00E-06	-	NR	-	0.0651 unit increase	NR	LINC01414,MIR124-2HG	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1072842:00:00	29160301	Fabbri C
rs12034885-?	3.00E-06	-	NR	-	0.0401 unit decrease	NR	KRT8P21,RN7SKP19	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1219764:56:00	29160301	Fabbri C
rs56060088-?	3.00E-06	-	NR	-	0.0402 unit decrease	NR	LINC01360	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1223819:05:00	29160301	Fabbri C
rs76191705-?	2.00E-06	-	NR	-	0.1863 unit decrease	NR	NRXN3	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1320882:39:00	29160301	Fabbri C
rs72819868-?	1.00E-06	-	NR	-	0.0974 unit decrease	NR	-	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1361727:01:00	29160301	Fabbri C
rs11813481-?	4.00E-06	-	NR	-	0.0451 unit increase	NR	NEURL1-AS1,NEURL1	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1725276:33:00	29160301	Fabbri C
rs117379618-?	2.00E-06	-	NR	-	0.1741 unit decrease	NR	HIGD1AP12,CHIAP3	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1856186:32:00	29160301	Fabbri C
rs116503642-?	5.00E-06	-	NR	-	0.1432 unit increase	NR	FEM1C,TICAM2	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	1926271:03:00	29160301	Fabbri C
rs3935545-?	5.00E-06	-	NR	-	0.0593 unit decrease	NR	LINC02361,NOC4L	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	2203038:19:00	29160301	Fabbri C
rs11167062-?	3.00E-06	-	NR	-	0.0448 unit increase	NR	MROH5	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	2357490:12:00	29160301	Fabbri C
rs78940746-?	3.00E-06	-	NR	-	0.1018 unit decrease	NR	ZNF639,KCNMB3	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	2988702:03:00	29160301	Fabbri C
rs4658888-?	4.00E-06	-	NR	-	0.0594 unit increase	NR	DISC1	Response to antidepressants (symptom improvement)	response to antidepressant	-	GCST007059	3864490:41:00	29160301	Fabbri C
SLC22A8-?	2.00E-06	(bupropion + escitalopram)	NR	-	-	-	-	Response to antidepressants in depression	response to antidepressant	unipolar depression	GCST006817	-	29998114	Gadad BS
rs10769025-?	1.00E-07	(escitalopram + placebo)	NR	-	-	-	ALX4	Response to antidepressants in depression	response to antidepressant	unipolar depression	GCST006817	737809:05:00	29998114	Gadad BS
LYPD6B-?	5.00E-06	(escitalopram + placebo)	NR	-	-	-	-	Response to antidepressants in depression	response to antidepressant	unipolar depression	GCST006817	-	29998114	Gadad BS
downstreamRASGEF1B-?	2.00E-06	(venlafaxine + mirtazapine)	NR	-	-	-	-	Response to antidepressants in depression	response to antidepressant	unipolar depression	GCST006817	-	29998114	Gadad BS
PPP5C-?	5.00E-06	(venlafaxine + mirtazapine)	NR	-	-	-	-	Response to antidepressants in depression	response to antidepressant	unipolar depression	GCST006817	-	29998114	Gadad BS
rs143397262-G	3.00E-07	-	NR	1.9093	-	NR	ADGRB3	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	1156163:04:00	33106475	Li QS
rs117613935-G	8.00E-06	-	NR	1.3999	-	NR	RELN	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	865817:38:00	33106475	Li QS
rs146026886-G	7.00E-06	-	NR	0.7195	-	NR	-	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	867641:52:00	33106475	Li QS
rs13225844-G	4.00E-06	-	NR	0.8685	-	NR	-	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	869464:20:00	33106475	Li QS
rs12155507-G	9.00E-06	-	NR	1.3945	-	NR	XRCC2,ATP5PBP3	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	2545367:53:00	33106475	Li QS
rs55731933-T	2.00E-06	-	NR	1.1856	-	NR	ADGRB1	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	2374574:32:00	33106475	Li QS
rs72789860-G	1.00E-06	-	NR	1.2469	-	NR	MTRNR2L7	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	627521:53:00	33106475	Li QS
rs182423331-T	4.00E-07	-	NR	1.2128	-	NR	ZNF248	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	629512:25:00	33106475	Li QS
rs72791791-G	8.00E-08	-	NR	0.8195	-	NR	ZNF25	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	632931:34:00	33106475	Li QS
rs72793759-G	2.00E-08	-	NR	0.8115	-	NR	PLD5P1,ZNF37A	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	635004:09:00	33106475	Li QS
rs59623126-G	3.00E-07	-	NR	1.2054	-	NR	PLD5P1,CCNYL4	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	636740:32:00	33106475	Li QS
rs150245813-T	8.00E-09	-	NR	0.7959	-	NR	PLD5P1	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	638407:32:00	33106475	Li QS
rs141905319-I	6.00E-07	-	NR	1.258	-	NR	CCNYL2,PABPC1P8	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	706348:29:00	33106475	Li QS
rs1941221-T	9.00E-06	-	NR	0.8826	-	NR	OPCML	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	2221423:02:00	33106475	Li QS
rs9543559-G	4.00E-06	-	NR	1.1606	-	NR	RPL21P108,RNY1P5	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	1238204:38:00	33106475	Li QS
rs938298-T	3.00E-06	-	NR	0.872	-	NR	SLFN11	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	589356:57:00	33106475	Li QS
rs143382920-G	6.00E-06	-	NR	0.6286	-	NR	NT5C3B	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	697261:24:00	33106475	Li QS
rs116934648-G	2.00E-06	-	NR	0.5847	-	NR	ODAD4	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	699366:49:00	33106475	Li QS
rs75709618-G	5.00E-06	-	NR	0.806	-	NR	CA10	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	869813:33:00	33106475	Li QS
rs201472877-I	6.00E-06	-	NR	1.8979	-	NR	MAG,CD22	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	588595:09:00	33106475	Li QS
rs148208076-G	6.00E-08	-	NR	2.1557	-	NR	TMX4	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	133362:19:00	33106475	Li QS
rs187931886-G	5.00E-06	-	NR	0.8668	-	NR	RNA5SP525	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	X:151053340	33106475	Li QS
rs45573441-T	6.00E-06	-	NR	0.4917	-	NR	XDH	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	522363:24:00	33106475	Li QS
rs111227877-G	4.00E-06	-	NR	1.7187	-	NR	CCR3,UQCRC2P1	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	771545:50:00	33106475	Li QS
rs73087860-T	9.00E-06	-	NR	0.7249	-	NR	PTPRG-AS1	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	1038408:36:00	33106475	Li QS
rs6764873-T	2.00E-07	-	NR	1.1591	-	NR	RNU6-1270P,PDZRN3	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	1222106:40:00	33106475	Li QS
rs141041718-T	2.00E-06	-	NR	0.5604	-	NR	ADTRP	Response to antidepressants (non-treatment-resistant vs treatment-resistant depression)	response to antidepressant	-	GCST012157	196286:38:00	33106475	Li QS
rs1375194-?	2.00E-07	-	NR	1.2578616	-	[1.15-1.37]	FAM98A,ATP6V0E1P3	Response to antidepressants in depression	response to antidepressant	unipolar depression,mood disorder	GCST003803	560032:10:00	27622933	Li QS
rs190662943-?	7.00E-07	-	NR	14.419	-	[5.177-40.161]	DPP10	Response to antidepressants in depression	response to antidepressant	unipolar depression,mood disorder	GCST003803	1919918:49:00	27622933	Li QS
rs75507262-?	1.00E-06	-	NR	2.3255813	-	[1.69-3.21]	LINC02814,TMEM78	Response to antidepressants in depression	response to antidepressant	unipolar depression,mood disorder	GCST003803	3820229:57:00	27622933	Li QS
rs10847303-?	2.00E-06	-	NR	1.242236	-	[1.14-1.36]	LINC02376	Response to antidepressants in depression	response to antidepressant	unipolar depression,mood disorder	GCST003803	2120867:20:00	27622933	Li QS
rs73086581-?	2.00E-06	-	NR	1.299	-	[1.169-1.444]	RNF24	Response to antidepressants in depression	response to antidepressant	unipolar depression,mood disorder	GCST003803	66631:18:00	27622933	Li QS
rs1126757-?	3.00E-06	(escitalopram)	0.48	-	10.4 unit increase	[NR]	IL11	Response to antidepressants	response to antidepressant	-	GCST000643	922827:24:00	20360315	Uher R
rs2136093-?	4.00E-07	(whole sample)	0.31	-	8.3 unit decrease	[NR]	-	Response to antidepressants	response to antidepressant	-	GCST000643	1506839:51:00	20360315	Uher R
rs16920624-?	7.00E-07	(whole sample)	0.07	-	16.0 unit decrease	[NR]	MIR4675	Response to antidepressants	response to antidepressant	-	GCST000643	342036:36:00	20360315	Uher R
rs2500535-A	9.00E-06	(genotype x drug)	0.06	-	29.7 unit decrease	[NR]	UST	Response to antidepressants	response to antidepressant	-	GCST000643	2483474:51:00	20360315	Uher R
rs4651156-?	3.00E-06	(nortriptyline)	0.29	-	12.6 unit decrease	[NR]	RGL1	Response to antidepressants	response to antidepressant	-	GCST000643	3064465:58:00	20360315	Uher R
rs11666579-?	3.00E-06	(genotype x drug)	0.48	-	14.4 unit increase	[NR]	SLC27A1	Response to antidepressants	response to antidepressant	-	GCST000643	291343:32:00	20360315	Uher R
rs1013696-?	4.00E-06	(genotype x drug)	0.22	-	17.8 unit decrease	[NR]	NOL4,ASXL3	Response to antidepressants	response to antidepressant	-	GCST000643	564018:46:00	20360315	Uher R
rs2500535-A	4.00E-08	(nortriptyline)	0.06	-	27.0 unit decrease	[NR]	UST	Response to antidepressants	response to antidepressant	-	GCST000643	2483474:51:00	20360315	Uher R
rs12080794-?	9.00E-06	-	NR	1.75	-	[1.33-2.27]	GPR157,SLC2A5	Response to antidepressant treatment (citalopram)	response to antidepressant	-	GCST002046	151522:06:00	23726668	Hunter AM
rs7816924-A	2.00E-07	-	NR	2.14	-	[1.53-2.99]	CSGALNACT1	Response to antidepressant treatment (citalopram)	response to antidepressant	-	GCST002046	328043:27:00	23726668	Hunter AM
rs10492002-?	4.00E-06	-	NR	1.64	-	[1.33-2.00]	ACSS3	Response to antidepressant treatment (citalopram)	response to antidepressant	-	GCST002046	1352524:37:00	23726668	Hunter AM
rs188352979-?	3.00E-07	-	NR	2.87	-	[2.47-3.28]	ACADSB,HMX3	Antidepressant treatment resistance (> 2 drugs prescribed)	response to antidepressant	-	GCST007355	2051524:44:00	30700811	Wigmore EM
rs145842949-?	4.00E-07	-	NR	2.42	-	[2.08-2.77]	MON1B	Antidepressant treatment resistance (> 2 drugs prescribed)	response to antidepressant	-	GCST007355	1285196:46:00	30700811	Wigmore EM
rs111968111-?	4.00E-07	-	NR	3	-	[2.58-3.42]	SRPK1,SLC26A8	Antidepressant treatment resistance (> 2 drugs prescribed)	response to antidepressant	-	GCST007355	598845:01:00	30700811	Wigmore EM
rs138583130-?	5.00E-07	-	NR	2.5	-	[2.13-2.87]	MUC19,CNTN1	Antidepressant treatment resistance (> 2 drugs prescribed)	response to antidepressant	-	GCST007355	677173:18:00	30700811	Wigmore EM
rs116902282-?	2.00E-07	-	NR	-	0.49 unit increase	[0.34-0.64]	LINC02651,RPL5P26	Antidepressant treatment resistance (number of drugs prescribed)	response to antidepressant	-	GCST007356	1161920:08:00	30700811	Wigmore EM
rs188352979-?	4.00E-07	-	NR	-	0.33 unit increase	[0.2-0.46]	ACADSB,HMX3	Antidepressant treatment resistance (number of drugs prescribed)	response to antidepressant	-	GCST007356	2051524:44:00	30700811	Wigmore EM
rs182041872-?	5.00E-07	-	NR	-	0.3 unit increase	[0.18-0.42]	HMX3,ACADSB	Antidepressant treatment resistance (number of drugs prescribed)	response to antidepressant	-	GCST007356	2051563:38:00	30700811	Wigmore EM
rs4400118-?	5.00E-07	-	NR	-	0.29 unit increase	[0.18-0.4]	KCNN2	Antidepressant treatment resistance (number of drugs prescribed)	response to antidepressant	-	GCST007356	1904603:48:00	30700811	Wigmore EM
rs7239368-?	9.00E-06	(remission)	0.42	1.45	-	[1.22-1.69]	NOL4	Response to citalopram treatment	response to antidepressant	-	GCST000509	567774:55:00	19846067	Garriock HA
rs6966038-?	5.00E-07	(response)	0.19	1.64	-	[1.35-1.99]	UBE3C,MNX1-AS1	Response to citalopram treatment	response to antidepressant	-	GCST000509	2618135:24:00	19846067	Garriock HA
rs6127921-?	3.00E-06	(response)	0.82	1.64	-	[1.33-2.04]	-	Response to citalopram treatment	response to antidepressant	-	GCST000509	951081:34:00	19846067	Garriock HA
rs809736-?	8.00E-06	(response)	0.17	1.52	-	[1.27-1.83]	RORA	Response to citalopram treatment	response to antidepressant	-	GCST000509	1017308:09:00	19846067	Garriock HA
rs6127921-?	1.00E-06	(remission)	0.81	1.75	-	[1.39-2.17]	-	Response to citalopram treatment	response to antidepressant	-	GCST000509	951081:34:00	19846067	Garriock HA
rs6966038-?	4.00E-07	(remission)	0.2	1.68	-	[1.37-2.04]	UBE3C,MNX1-AS1	Response to citalopram treatment	response to antidepressant	-	GCST000509	2618135:24:00	19846067	Garriock HA
rs2830840-?	5.00E-06	(remission)	0.46	1.47	-	[1.23-1.72]	EIF4A1P1	Response to citalopram treatment	response to antidepressant	-	GCST000509	454904:48:00	19846067	Garriock HA
rs7715172-G	3.00E-06	(EA + AA - GSE)	0.071	-	-	-	EGFLAM	Response to citalopram treatment	response to antidepressant	-	GCST001591	640884:52:00	22760553	Adkins DE
rs17135437-A	3.00E-08	(EA + AA - Vision\hearing)	0.019	-	-	-	COL26A1	Response to citalopram treatment	response to antidepressant	-	GCST001591	1691218:53:00	22760553	Adkins DE
rs3810046-T	5.00E-07	(EA + AA - Overall tolerability)	0.456	-	-	-	LAMA1,RNU6-916P	Response to citalopram treatment	response to antidepressant	-	GCST001591	115712:23:00	22760553	Adkins DE
rs13430864-G	5.00E-07	(EA + AA - Dizziness)	0.04	-	-	-	BZW1-AS1,AOX2P	Response to citalopram treatment	response to antidepressant	-	GCST001591	3346400:36:00	22760553	Adkins DE
rs6040399-T	7.00E-07	(EA + AA - Dizziness)	0.308	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	186292:43:00	22760553	Adkins DE
rs17135437-A	3.00E-06	(AA - Vision\hearing)	NR	-	-	-	COL26A1	Response to citalopram treatment	response to antidepressant	-	GCST001591	1691218:53:00	22760553	Adkins DE
rs6040399-T	1.00E-06	(AA - Dizziness)	NR	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	186292:43:00	22760553	Adkins DE
rs11935103-T	1.00E-06	(EA + AA - GSE)	0.262	-	-	-	F11-AS1	Response to citalopram treatment	response to antidepressant	-	GCST001591	3106957:01:00	22760553	Adkins DE
rs2903308-A	2.00E-06	(EA + AA - Overall tolerability)	0.461	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	226066:28:00	22760553	Adkins DE
rs4502542-T	2.00E-06	(EA + AA - GSE)	0.017	-	-	-	FHIT	Response to citalopram treatment	response to antidepressant	-	GCST001591	998924:34:00	22760553	Adkins DE
rs6563353-A	2.00E-06	(EA + AA - GSE)	0.177	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	1392614:37:00	22760553	Adkins DE
rs16965962-T	3.00E-07	(EA + AA - GSE)	0.03	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	1752590:52:00	22760553	Adkins DE
rs6646773-C	1.00E-06	(EA + AA - GSE)	0.076	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	X:117088295	22760553	Adkins DE
rs6764050-G	9.00E-07	(EA + AA - GSE)	0.023	-	-	-	RTP2,SST	Response to citalopram treatment	response to antidepressant	-	GCST001591	3128273:03:00	22760553	Adkins DE
rs4398173-G	4.00E-06	(EA - Overall tolerability)	NR	-	-	-	RNU6-916P,LAMA1	Response to citalopram treatment	response to antidepressant	-	GCST001591	115703:09:00	22760553	Adkins DE
rs16965962-T	3.00E-07	(AA - GSE)	NR	-	-	-	-	Response to citalopram treatment	response to antidepressant	-	GCST001591	1752590:52:00	22760553	Adkins DE
rs11935103-T	2.00E-06	(EA - GSE)	NR	-	-	-	F11-AS1	Response to citalopram treatment	response to antidepressant	-	GCST001591	3106957:01:00	22760553	Adkins DE
rs365836-A	2.00E-06	-	NR	4.79	-	[2.38-9.64]	CUX1	Response to antidepressants	response to antidepressant	-	GCST001528	1702783:11:00	22584459	Sasayama D
rs1807204-T	3.00E-07	-	0.707	1.30226	-	[1.2-1.4]	DHX8	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	724843:41:00	35712048	Pain O
rs3900596-A	3.00E-06	-	0.814	0.7659	-	[0.65-0.88]	TLCD4-RWDD3,TLCD4	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1585900:53:00	35712048	Pain O
rs34170867-?	3.00E-06	-	0.867	1.39682	-	[1.26-1.54]	SAMD12	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1973736:07:00	35712048	Pain O
rs545208792-?	3.00E-06	-	0.603	0.71979	-	[0.58-0.86]	MYT1L	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	32610:28:00	35712048	Pain O
rs3976883-?	4.00E-06	-	0.769	1.39738	-	[1.26-1.54]	CBWD2	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1891111:10:00	35712048	Pain O
rs10968196-G	4.00E-06	-	0.9	1.44123	-	[1.29-1.6]	LINGO2,CTAGE12P	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	465409:53:00	35712048	Pain O
rs11302946-?	4.00E-06	-	0.201	1.50185	-	[1.33-1.67]	B4GALNT3	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	8447:08:00	35712048	Pain O
rs7567724-G	4.00E-06	-	0.874	1.45601	-	[1.3-1.62]	COLEC11	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	60223:06:00	35712048	Pain O
rs141235407-G	5.00E-06	-	0.98	3.49069	-	[2.95-4.03]	DDX54	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1886435:32:00	35712048	Pain O
rs78612462-G	5.00E-06	-	0.865	1.39361	-	[1.25-1.54]	RAD51B	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1144880:38:00	35712048	Pain O
rs7753048-C	6.00E-06	-	0.877	1.39934	-	[1.25-1.54]	CCN2,ENPP1	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	2198281:47:00	35712048	Pain O
rs112409802-G	7.00E-06	-	0.764	1.28108	-	[1.17-1.39]	CLSTN2	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	2341611:00:00	35712048	Pain O
rs77452989-A	8.00E-06	-	0.93	1.55473	-	[1.36-1.75]	CNN3-DT,ALG14	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1582753:23:00	35712048	Pain O
rs11357137-?	8.00E-06	-	0.254	0.76682	-	[0.65-0.88]	TMPO,PPIAP8	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1642845:48:00	35712048	Pain O
rs140712235-?	8.00E-06	-	0.795	1.35581	-	[1.22-1.49]	ABCG2	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	1469120:55:00	35712048	Pain O
rs11652675-G	9.00E-06	-	0.964	2.02304	-	[1.71-2.33]	WFIKKN2,MIR8059	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	846697:13:00	35712048	Pain O
rs2027719-T	1.00E-05	-	0.445	1.23134	-	[1.14-1.32]	D21S2088E	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	389467:49:00	35712048	Pain O
rs6962925-A	1.00E-05	-	0.566	0.80092	-	[0.7-0.9]	SEC61G-DT,EGFR	Remission after antidepressant treatment in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244577	913960:18:00	35712048	Pain O
rs745581-C	2.00E-06	-	NR	-	0.572 unit increase	-	LINC01250,MYT1L	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	45490:54:00	36228427	Yuan J
rs1883901-A	4.00E-06	-	NR	-	0.494 unit increase	-	MDGA1	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	627726:55:00	36228427	Yuan J
rs10948514-T	2.00E-08	-	NR	-	0.454 unit increase	-	CYP2AC1P,RHAG	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	826540:40:00	36228427	Yuan J
rs10226923-A	3.00E-06	-	NR	-	1.768 unit increase	-	LINC02476,GTF3AP6	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	1983110:30:00	36228427	Yuan J
rs147165257-G	4.00E-06	-	NR	-	1.774 unit increase	-	LINC02476	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	1991742:07:00	36228427	Yuan J
rs546236721-C	5.00E-06	-	NR	-	0.425 unit increase	-	KSR1P1,CHEK2P5	Response to antidepressants in major depressive disorder	response to antidepressant	major depressive disorder	GCST90244559	697630:10:00	36228427	Yuan J
rs1026501-G	4.00E-06	-	NR	0.21	-	[0.11-0.4]	SYNPO2,MYOZ2	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275121	1984872:36:00	37015192	Men X
rs12347401-C	5.00E-06	-	NR	0.11	-	[0.04-0.28]	ASS1,FUBP3	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275121	2176312:55:00	37015192	Men X
rs11243867-T	5.00E-06	-	NR	0.11	-	[0.04-0.28]	FUBP3,ASS1	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275121	2176324:30:00	37015192	Men X
rs12336064-A	5.00E-06	-	NR	0.11	-	[0.04-0.28]	ASS1,FUBP3	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275121	2176151:52:00	37015192	Men X
rs2745253-A	5.00E-06	-	NR	0.27	-	[0.15-0.47]	TMCO4	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275121	329467:47:00	37015192	Men X
rs6844137-T	5.00E-06	-	NR	0.15	-	[0.07-0.34]	SYNPO2	Remission after sertraline plus olanzapine treatment in psychotic depression	response to sertraline,psychotic symptom measurement,response to olanzapine	major depressive episode,unipolar depression	GCST90275123	1984219:35:00	37015192	Men X
rs78087832-?	6.00E-07	-	NR	2.731	-	[1.933-3.857]	CUL3	Response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003806	3743336:20:00	27622933	Li QS
rs112106319-?	1.00E-06	-	NR	2.3255813	-	[1.59-3.4]	DELEC1,TNC	Response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003806	1918251:19:00	27622933	Li QS
rs73425402-?	1.00E-06	-	NR	20.833332	-	[8.26-52.63]	NAV3	Response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003806	1291737:18:00	27622933	Li QS
rs190783615-?	2.00E-17	-	NR	15.18	-	[3.095-74.439]	-	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	X:142772620	27622933	Li QS
rs201203751-?	5.00E-07	-	NR	4.009	-	[2.537-6.336]	FYB1	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	653396:36:00	27622933	Li QS
rs183124483-?	6.00E-07	-	NR	14.925372	-	[6.85-32.26]	NLK	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	468517:28:00	27622933	Li QS
rs56388524-?	7.00E-07	-	NR	1.798	-	[1.451-2.228]	HCN1	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	762629:19:00	27622933	Li QS
rs143405544-?	7.00E-07	-	NR	6.711409	-	[2.44-18.52]	ADAMTS6	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	1091001:17:00	27622933	Li QS
rs183042538-?	8.00E-07	-	NR	1.431	-	[1.249-1.638]	ZHX3	Non-response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003804	686643:40:00	27622933	Li QS
rs200855945-?	4.00E-07	-	NR	4.929	-	[2.35-10.34]	BHLHE41,SSPN	Response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003806	435428:01:00	27622933	Li QS
rs112538845-?	6.00E-07	-	NR	1.637	-	[1.366-1.961]	ENPP6,STOX2	Response to bupropion and depression	unipolar depression,response to bupropion,mood disorder	-	GCST003806	3068078:35:00	27622933	Li QS
rs1074145-?	2.00E-16	(S-DCT/S-CT ratio)	0.162	-	-	-	RPL7AP52,CYP2C9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	1582044:49:00	24528284	Ji Y
rs1074145-?	4.00E-09	(S-CT concentration)	0.162	-	-	-	RPL7AP52,CYP2C9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	1582044:49:00	24528284	Ji Y
rs9747992-?	2.00E-07	(S-DCT concentration)	0.086	-	-	-	CBX4,LINC01977	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	1330534:21:00	24528284	Ji Y
rs2059865-?	3.00E-07	(S-DCT concentration)	0.235	-	-	-	PDZD2	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	529443:46:00	24528284	Ji Y
rs55734731-?	4.00E-07	(S-CT concentration, adjusted for CYP2C19)	0.124	-	-	-	LINC01370,HSPE1P1	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	665749:32:00	24528284	Ji Y
rs71607999-?	7.00E-09	(S-DCT/S-CT ratio, adjusted for CYP2C19)	0.165	-	-	-	-	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	3137836:37:00	24528284	Ji Y
rs11934750-?	1.00E-07	(S-DCT/S-CT ratio, adjusted for CYP2C19)	0.16	-	-	-	-	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	466050:23:00	24528284	Ji Y
rs77724872-?	7.00E-07	(S-DCT concentration, adjusted for CYP2C19)	0.047	-	-	-	TXNRD1,CHST11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	1739357:22:00	24528284	Ji Y
rs8102150-?	7.00E-07	(S-DCT concentration, adjusted for CYP2C19)	0.028	-	-	-	TSKS,CPT1C	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	828803:30:00	24528284	Ji Y
rs1722229-?	1.00E-06	(S-CT concentration, adjusted for CYP2C19)	0.034	-	-	-	MYL10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	1694055:17:00	24528284	Ji Y
rs117020818-?	7.00E-07	(S-DCT concentration)	0.046	-	-	-	RASSF10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	218471:16:00	24528284	Ji Y
rs1058172-?	2.00E-16	(S-DDCT concentration)	0.155	-	-	-	SEPTIN3	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	699968:47:00	24528284	Ji Y
rs1058172-?	8.00E-16	(S-DDCT/S-DCT ratio)	0.155	-	-	-	CYP2D6,NDUFA6-DT	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	702147:26:00	24528284	Ji Y
rs1065852-?	2.00E-16	(S-DDCT concentration)	0.215	-	-	-	CYP2D6,NDUFA6-DT	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	702200:12:00	24528284	Ji Y
rs1065852-?	8.00E-16	(S-DDCT/S-DCT ratio)	0.215	-	-	-	CYP2D6,NDUFA6-DT	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	unipolar depression,response to selective serotonin reuptake inhibitor	-	GCST002549	702200:12:00	24528284	Ji Y
rs3825243-A	4.00E-08	-	NR	-	-	-	LYZ,YEATS4	Response to SSRI in MDD or conscientiouness	conscientiousness measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005836	1155962:59:00	29559929	Amare AT
rs2979204-T	8.00E-11	-	NR	-	-	-	PRAG1	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	140697:07:00	29559929	Amare AT
rs11990063-T	9.00E-09	-	NR	-	-	-	MSRA	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	171802:45:00	29559929	Amare AT
rs35792458-C	1.00E-12	-	NR	-	-	-	XKR6	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	182756:41:00	29559929	Amare AT
rs12555870-G	1.00E-08	-	NR	-	-	-	-	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	389137:46:00	29559929	Amare AT
rs4761545-G	8.00E-10	-	NR	-	-	-	RN7SKP263	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	1567223:32:00	29559929	Amare AT
rs144733372-G	3.00E-11	-	NR	-	-	-	PLEKHM1	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	758131:16:00	29559929	Amare AT
rs11082011-C	4.00E-08	-	NR	-	-	-	CELF4	Remission after SSRI treatment in MDD or neuroticism	neuroticism measurement,response to selective serotonin reuptake inhibitor	unipolar depression	GCST005835	626103:59:00	29559929	Amare AT
rs55679149-T	8.00E-07	-	NR	-	-	-	PTGES3P1,GBP1	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	1484478:35:00	29559929	Amare AT
rs11728985-T	4.00E-07	-	NR	-	-	-	C4orf33	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	2151925:20:00	29559929	Amare AT
rs11155372-T	1.00E-07	-	NR	-	-	-	UTRN	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	2411649:22:00	29559929	Amare AT
rs7828021-C	4.00E-07	-	NR	-	-	-	PSAT1P1	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	828798:54:00	29559929	Amare AT
rs1411216-A	5.00E-07	-	NR	-	-	-	IZUMO3	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	408678:56:00	29559929	Amare AT
rs7189979-C	3.00E-07	-	NR	-	-	-	SNX29	Remission after SSRI treatment in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005833	208954:50:00	29559929	Amare AT
rs7555693-A	1.00E-06	-	NR	-	-	-	-	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	1771599:37:00	29559929	Amare AT
rs9321987-A	5.00E-07	-	NR	-	-	-	UTRN	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	2411825:08:00	29559929	Amare AT
rs352759-T	6.00E-07	-	NR	-	-	-	TUSC3	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	262378:05:00	29559929	Amare AT
rs7828021-C	7.00E-08	-	NR	-	-	-	PSAT1P1	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	828798:54:00	29559929	Amare AT
rs11591827-A	9.00E-07	-	NR	-	-	-	RPA2P2	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	1352145:26:00	29559929	Amare AT
rs7189979-C	2.00E-07	-	NR	-	-	-	SNX29	Response to SSRI in MDD or openness	response to selective serotonin reuptake inhibitor,openness measurement	unipolar depression	GCST005834	208954:50:00	29559929	Amare AT
chr5:28096209-A	3.00E-08	-	NR	-	1.11907 unit increase	[0.73-1.51]	-	Total cholesterol levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012323	-	33824429	Fjukstad KK
chr13:97478887-A	2.00E-08	-	NR	-	0.611097 unit increase	[0.4-0.82]	-	Total cholesterol levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012323	-	33824429	Fjukstad KK
rs72674216-A	9.00E-08	-	NR	-	0.959753 unit increase	[0.61-1.31]	LINC01739,LINC00466	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1051322:59:00	33824429	Fjukstad KK
rs143113754-A	1.00E-07	-	NR	-	1.03895 unit increase	[0.66-1.42]	SLC35D1	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1116928:49:00	33824429	Fjukstad KK
rs17097330-G	1.00E-07	-	NR	-	1.01366 unit increase	[0.64-1.39]	IL12RB2	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1123198:19:00	33824429	Fjukstad KK
rs56370400-T	4.00E-07	-	NR	-	1.04809 unit increase	[0.65-1.45]	RN7SL392P,RNU6-1031P	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1127157:04:00	33824429	Fjukstad KK
rs72721860-T	3.00E-07	-	NR	-	1.0167 unit increase	[0.63-1.4]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1640881:45:00	33824429	Fjukstad KK
rs115128816-T	4.00E-07	-	NR	-	1.20976 unit increase	[0.75-1.67]	MTATP6P14	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1779789:13:00	33824429	Fjukstad KK
rs114204012-A	4.00E-07	-	NR	-	1.28919 unit increase	[0.8-1.78]	VAV3	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1793931:48:00	33824429	Fjukstad KK
rs71673444-T	2.00E-08	-	NR	-	1.29895 unit increase	[0.85-1.75]	KCND3	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1866335:36:00	33824429	Fjukstad KK
rs11808287-T	3.00E-07	-	NR	-	0.503145 unit increase	[0.31-0.69]	TRIM33,MRPL57P1	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1906041:44:00	33824429	Fjukstad KK
rs41266605-G	4.00E-07	-	NR	-	1.0687 unit increase	[0.66-1.48]	BNIPL	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	2517279:52:00	33824429	Fjukstad KK
chr1:164471324-G	1.00E-07	-	NR	-	1.46 unit increase	[1-1.92]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr1:173889861-T	3.00E-07	-	NR	-	1.01135 unit increase	[0.63-1.4]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr1:204278060-A	3.00E-07	-	NR	-	1.01468 unit increase	[0.63-1.4]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr1:209201361-T	1.00E-07	-	NR	-	1.17 unit increase	[0.7-1.64]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr2:34777314-A	8.00E-08	-	NR	-	0.830836 unit increase	[0.53-1.13]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr2:58985712-A	3.00E-07	-	NR	-	1.33771 unit increase	[0.83-1.85]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr2:184928538-A	2.00E-07	-	NR	-	1.35648 unit increase	[0.85-1.87]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr2:216859235-C	4.00E-07	-	NR	-	1.29903 unit increase	[0.8-1.8]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:3663265-T	1.00E-07	-	NR	-	1.17705 unit increase	[0.74-1.61]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:46100303-T	1.00E-07	-	NR	-	1.00724 unit increase	[0.64-1.38]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:47010116-A	6.00E-08	-	NR	-	1.1613 unit increase	[0.74-1.58]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:47251391-G	5.00E-08	-	NR	-	1.16451 unit increase	[0.75-1.58]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:47418822-T	1.00E-07	-	NR	-	1.14109 unit increase	[0.72-1.56]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr16:2349706-A	4.00E-08	-	NR	-	1.44005 unit increase	[0.93-1.95]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr17:29421869-C	3.00E-08	-	NR	-	1.31621 unit increase	[0.85-1.78]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:103798624-C	5.00E-07	-	NR	-	0.93273 unit increase	[0.57-1.29]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:107593376-C	3.00E-07	-	NR	-	1.27038 unit increase	[0.79-1.75]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:144726355-T	1.00E-07	-	NR	-	1.31262 unit increase	[0.83-1.8]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:152529052-T	1.00E-07	-	NR	-	1.22374 unit increase	[0.77-1.67]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:153086913-T	1.00E-07	-	NR	-	1.05184 unit increase	[0.66-1.44]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:185847872-A	2.00E-07	-	NR	-	1.22305 unit increase	[0.77-1.68]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr3:196705485-A	4.00E-07	-	NR	-	1.17745 unit increase	[0.72-1.63]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
rs72749636-T	4.00E-10	-	NR	-	1.52943 unit increase	[1.05-2]	CDH6	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	520083:15:00	33824429	Fjukstad KK
rs184012381-T	4.00E-09	-	NR	-	1.54483 unit increase	[1.04-2.05]	CDH6	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	522028:01:00	33824429	Fjukstad KK
rs6893037-G	3.00E-09	-	NR	-	1.41713 unit increase	[0.95-1.88]	PCDH1,DELE1	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	2365322:06:00	33824429	Fjukstad KK
chr6:21215343-C	4.00E-08	-	NR	-	1.46107 unit increase	[0.94-1.98]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
rs35497646-A	4.00E-09	-	NR	-	1.21066 unit increase	[0.81-1.61]	SUPT3H	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	745439:03:00	33824429	Fjukstad KK
chr6:102207556-T	5.00E-08	-	NR	-	1.01604 unit increase	[0.65-1.38]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr7:20000997-C	3.00E-08	-	NR	-	1.35924 unit increase	[0.88-1.84]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr8:4432863-A	3.00E-08	-	NR	-	1.11446 unit increase	[0.72-1.5]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
rs113613039-A	5.00E-09	-	NR	-	1.76 unit increase	[1.3-2.22]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	355706:48:00	33824429	Fjukstad KK
rs113220477-G	1.00E-07	-	NR	-	1.1197 unit increase	[0.71-1.53]	FRMD4A	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	237779:49:00	33824429	Fjukstad KK
rs76296059-C	5.00E-09	-	NR	-	1.457 unit increase	[0.97-1.94]	NEBL	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	348061:04:00	33824429	Fjukstad KK
rs112817646-A	1.00E-08	-	NR	-	1.42197 unit increase	[0.94-1.9]	VN1R53P	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	623312:28:00	33824429	Fjukstad KK
chr10:37803153-T	3.00E-08	-	NR	-	1.34186 unit increase	[0.87-1.81]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
chr10:65439003-A	4.00E-08	-	NR	-	1.08009 unit increase	[0.7-1.46]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
rs117302061-G	1.00E-08	-	NR	-	1.15793 unit increase	[0.77-1.55]	RPS3AP5	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1409816:06:00	33824429	Fjukstad KK
rs151137139-G	2.00E-07	-	NR	-	1.55 unit increase	[1.09-2.01]	WBP1L	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1712813:43:00	33824429	Fjukstad KK
rs151010944-A	1.00E-09	-	NR	-	1.29293 unit increase	[0.88-1.71]	FAM204A,CASC2	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1971581:51:00	33824429	Fjukstad KK
rs73126876-C	4.00E-09	-	NR	-	1.16459 unit increase	[0.78-1.55]	PDZRN4	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	689736:04:00	33824429	Fjukstad KK
chr14:84603367-T	2.00E-08	-	NR	-	1.06614 unit increase	[0.7-1.44]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	-	33824429	Fjukstad KK
rs17088924-C	3.00E-09	-	NR	-	1.14425 unit increase	[0.77-1.52]	-	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	triglyceride measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012322	1076770:34:00	33824429	Fjukstad KK
rs139602194-T	1.00E-08	-	0.02	-	2.83 unit increase	[1.86-3.80]	CRACD	HDL levels x SSRI levels interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012330	936181:47:00	33824429	Fjukstad KK
rs141881809-G	6.00E-10	-	0.02	-	20.6 unit increase	[14.13-27.07]	NCAM1	LDL levels x SSRI levels interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012329	1884641:53:00	33824429	Fjukstad KK
rs141881809-G	3.00E-07	-	0.02	-	19.22 unit increase	[11.90-26.54]	NCAM1	Total cholesterol levels x SSRI levels interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012328	1884641:53:00	33824429	Fjukstad KK
rs12037821-T	1.00E-07	-	NR	-	3.10609 unit increase	[1.96-4.25]	PLCH2	BMI x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	schizophrenia,bipolar disorder	GCST012326	40938:56:00	33824429	Fjukstad KK
chr2:79261154-A	2.00E-07	-	NR	-	5.74191 unit increase	[3.61-7.88]	-	BMI x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	schizophrenia,bipolar disorder	GCST012326	-	33824429	Fjukstad KK
chr2:241422788-A	9.00E-08	-	NR	-	3.28886 unit increase	[2.09-4.49]	-	BMI x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	schizophrenia,bipolar disorder	GCST012326	-	33824429	Fjukstad KK
chr3:115530388-A	2.00E-07	-	NR	-	2.06412 unit increase	[1.29-2.84]	-	BMI x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	schizophrenia,bipolar disorder	GCST012326	-	33824429	Fjukstad KK
rs149932-G	4.00E-07	-	NR	-	0.21263 unit decrease	[0.13-0.29]	EPB41	HDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012325	481955:08:00	33824429	Fjukstad KK
chr2:205603512-G	5.00E-07	-	NR	-	0.497975 unit increase	[0.31-0.69]	-	HDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012325	-	33824429	Fjukstad KK
rs597821-A	3.00E-07	-	NR	-	0.196185 unit decrease	[0.12-0.27]	LINC02646	HDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,high density lipoprotein cholesterol measurement	bipolar disorder,schizophrenia	GCST012325	2172669:38:00	33824429	Fjukstad KK
rs148697385-T	5.00E-07	-	NR	-	0.86429 unit increase	[0.53-1.2]	CSMD2	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	568392:39:00	33824429	Fjukstad KK
rs12121280-T	2.00E-08	-	NR	-	0.841469 unit increase	[0.55-1.13]	APCS,OR10AE1P	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	2659745:51:00	33824429	Fjukstad KK
chr1:214011756-C	1.00E-07	-	NR	-	0.494979 unit increase	[0.31-0.68]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	-	33824429	Fjukstad KK
rs34263784-G	3.00E-09	-	NR	-	1.18594 unit increase	[0.8-1.58]	MMADHC-DT	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	2494973:09:00	33824429	Fjukstad KK
chr2:150662104-A	1.00E-07	-	NR	-	0.807137 unit increase	[0.51-1.1]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	-	33824429	Fjukstad KK
chr2:150853933-G	7.00E-08	-	NR	-	0.916463 unit increase	[0.59-1.25]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	-	33824429	Fjukstad KK
chr3:2090801-G	2.00E-07	-	NR	-	0.430703 unit increase	[0.27-0.59]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	-	33824429	Fjukstad KK
rs115000927-A	1.00E-08	-	NR	-	1.02638 unit increase	[0.68-1.38]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	468273:22:00	33824429	Fjukstad KK
rs7716507-G	2.00E-09	-	NR	-	0.424746 unit increase	[0.29-0.56]	ADAMTS6	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	1087063:13:00	33824429	Fjukstad KK
rs7750294-T	1.00E-08	-	NR	-	0.795648 unit increase	[0.52-1.07]	MLIP-AS1,MLIP	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	900995:32:00	33824429	Fjukstad KK
rs6969759-G	8.00E-09	-	NR	-	0.728548 unit increase	[0.48-0.97]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	1131599:55:00	33824429	Fjukstad KK
chr7:80557095-C	4.00E-08	-	NR	-	0.576886 unit increase	[0.37-0.78]	-	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	-	33824429	Fjukstad KK
rs72777665-A	5.00E-07	-	NR	-	0.727833 unit increase	[0.45-1.01]	USP6NL	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	192031:26:00	33824429	Fjukstad KK
rs17539426-A	8.00E-08	-	NR	-	0.867186 unit increase	[0.55-1.18]	USP6NL-AS1,ECHDC3	LDL levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	low density lipoprotein cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012324	194493:33:00	33824429	Fjukstad KK
chr2:150554783-G	1.00E-07	-	NR	-	1.19482 unit increase	[0.75-1.64]	-	Total cholesterol levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	total cholesterol measurement,response to selective serotonin reuptake inhibitor	bipolar disorder,schizophrenia	GCST012323	-	33824429	Fjukstad KK
rs7583903-A	3.00E-08	-	0.02	-	62.78 unit increase	[40.85-84.71]	GPC1	BMI x SSRI levels interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	bipolar disorder,schizophrenia	GCST012331	4006574:20:00	33824429	Fjukstad KK
rs148756956-C	2.00E-08	-	0.02	-	32.04 unit increase	[20.99-43.09]	PTPRT	BMI x SSRI levels interaction in schizophrenia or bipolar disorder	response to selective serotonin reuptake inhibitor,body mass index	bipolar disorder,schizophrenia	GCST012331	718807:14:00	33824429	Fjukstad KK
rs17158930-G	3.00E-07	-	0.193	-	0.3082 unit decrease	[NR]	DOCK4	Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio)	concentration dose ratio,response to antidepressant	unipolar depression,schizophrenia,bipolar disorder	GCST002891	1864525:02:00	25944848	Athanasiu L
rs112534819-T	2.00E-06	-	0.02	-	0.37 unit increase	[0.21-0.53]	RN7SL383P,LINC02224	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	745215:40:00	30468137	Fabbri C
rs188509130-T	3.00E-06	-	0.01	-	0.34 unit increase	[0.2-0.48]	DPY19L1P1	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	544059:41:00	30468137	Fabbri C
rs10860592-T	3.00E-06	-	0.19	-	0.09 unit decrease	[0.051-0.129]	-	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1309257:54:00	30468137	Fabbri C
rs72865845-C	4.00E-06	-	0.22	-	0.09 unit increase	[0.051-0.129]	EVPL	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1267005:35:00	30468137	Fabbri C
rs144150047-T	5.00E-06	-	0.04	-	0.25 unit increase	[0.15-0.35]	-	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	X:125515825	30468137	Fabbri C
rs151126591-T	5.00E-06	-	0.01	-	0.35 unit increase	[0.19-0.51]	STK3	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1641009:01:00	30468137	Fabbri C
rs7665833-A	1.00E-07	-	0.14	2.03	-	[1.78-2.28]	PGBD4P4,LINC02479	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	2174336:42:00	30468137	Fabbri C
rs7735612-C	6.00E-07	-	0.4	1.63	-	[1.43-1.83]	SLIT3	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	2818050:27:00	30468137	Fabbri C
rs2898168-?	2.00E-06	-	0.68	1.6666665	-	-	KRTAP13-3,KRTAP13-1	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	506859:04:00	30468137	Fabbri C
nsv831124-?	3.00E-06	-	0.54	1.4285715	-	-	-	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	-	30468137	Fabbri C
rs4863995-T	4.00E-06	-	0.22	1.67	-	[1.45-1.89]	GAPDHP56,PGBD4P4	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	2174952:47:00	30468137	Fabbri C
rs6852702-A	4.00E-06	-	0.09	2.07	-	[1.76-2.38]	GAPDHP56	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	2175264:32:00	30468137	Fabbri C
rs12006913-A	4.00E-06	-	0.12	2.13	-	[1.82-2.44]	PTCHD1	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	X:23358454	30468137	Fabbri C
nsv527355-A	5.00E-06	-	0.47	1.44	-	[1.28-1.6]	-	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007665	-	30468137	Fabbri C
rs242999-C	1.00E-06	-	0.39	1.85	-	[1.44-2.37]	LINC01643	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	568520:34:00	30468137	Fabbri C
rs73837957-A	2.00E-06	-	0.15	2.73	-	[1.81-4.11]	CCSER1	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	1528053:18:00	30468137	Fabbri C
rs9895559-A	2.00E-06	-	0.45	1.85	-	[1.43-2.38]	RPL23AP73,SLC13A5	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	112217:54:00	30468137	Fabbri C
rs80080484-?	4.00E-06	-	0.97	5.882353	-	[2.7-12.5]	LINC01910,LARP7P3	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	1173404:30:00	30468137	Fabbri C
rs12745534-?	5.00E-06	-	0.87	2.2222223	-	[1.59-3.12]	HIVEP3	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	698177:19:00	30468137	Fabbri C
rs12564480-?	9.00E-07	-	0.88	2.4390244	-	[1.72-3.57]	OPN3,WDR64	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	4027772:24:00	30468137	Fabbri C
rs1841915-?	1.00E-06	-	0.61	1.8518518	-	[1.45-2.33]	ZNF385D,ZNF385D-AS1	Treatment resistant depression	treatment resistant depression,response to antidepressant	-	GCST007667	359568:47:00	30468137	Fabbri C
rs952614-A	2.00E-06	-	0.31	-	0.08 unit increase	[0.041-0.119]	-	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1826304:01:00	30468137	Fabbri C
rs12564480-C	4.00E-07	-	0.12	-	0.12 unit increase	[0.081-0.159]	OPN3,WDR64	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	4027772:24:00	30468137	Fabbri C
rs8086741-C	7.00E-07	-	0.01	-	0.37 unit decrease	[0.23-0.51]	LDLRAD4	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	222638:30:00	30468137	Fabbri C
rs79035215-T	7.00E-07	-	0.01	-	0.31 unit decrease	[0.19-0.43]	ZDHHC3	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	749247:06:00	30468137	Fabbri C
rs1991346-G	7.00E-07	-	0.42	-	0.08 unit decrease	[0.041-0.119]	SGCZ	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	238240:53:00	30468137	Fabbri C
rs1334063-T	9.00E-07	-	0.33	-	0.08 unit increase	[0.041-0.119]	RFX3-AS1	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	60878:15:00	30468137	Fabbri C
rs73837957-A	1.00E-06	-	0.15	-	0.12 unit decrease	[0.081-0.159]	CCSER1	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1528053:18:00	30468137	Fabbri C
rs2075855-A	1.00E-06	-	0.08	-	0.14 unit increase	[0.081-0.199]	MUC5B	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	20473:10:00	30468137	Fabbri C
rs138362018-G	2.00E-06	-	0.01	-	0.31 unit decrease	[0.17-0.45]	TGM4	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	748478:34:00	30468137	Fabbri C
rs10514108-T	1.00E-06	-	0.1	-	0.13 unit decrease	[0.071-0.189]	ARSB	Depressive symptom improvement	depressive symptom measurement,response to antidepressant	-	GCST007666	1313497:04:00	30468137	Fabbri C
rs6916777-A	1.00E-06	-	NR	-	14.03 unit increase	[8.47-19.59]	RNF217-AS1	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	2082176:28:00	33589590	Marshe VS
rs12597726-A	9.00E-06	-	NR	-	14.25 unit decrease	[8.06-20.44]	PIEZO1	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	1479247:33:00	33589590	Marshe VS
rs6696969-C	4.00E-06	-	NR	-	15.19 unit decrease	[8.89-21.49]	-	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	1331246:36:00	33589590	Marshe VS
rs10204266-T	4.00E-06	-	NR	-	22.49 unit decrease	[13.12-31.86]	ADCY3,DNAJC27	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	415399:00:00	33589590	Marshe VS
rs74865692-T	2.00E-06	-	NR	-	23.67 unit decrease	[14.02-33.33]	ERBB4	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	3538290:24:00	33589590	Marshe VS
rs9905054-G	4.00E-06	-	NR	-	21.58 unit decrease	[12.58-30.58]	RNA5SP446,CACNG4	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	1115644:46:00	33589590	Marshe VS
rs77547060-C	2.00E-06	-	NR	-	25.59 unit decrease	[15.25-35.93]	SLC12A5	Response to antidepressants (symptom improvement)	depressive symptom measurement,response to antidepressant	unipolar depression	GCST011528	767241:46:00	33589590	Marshe VS
rs6916777-A	4.00E-06	-	NR	2.58	-	[1.73-3.85]	RNF217-AS1	Remission after antidepressant treatment in major depression	remission,response to antidepressant	unipolar depression	GCST011531	2082176:28:00	33589590	Marshe VS
rs2962466-G	2.00E-06	-	NR	0.37	-	[0.24-0.56]	-	Remission after antidepressant treatment in major depression	remission,response to antidepressant	unipolar depression	GCST011531	1046251:03:00	33589590	Marshe VS
rs12597726-A	1.00E-06	-	NR	0.33	-	[0.21-0.51]	PIEZO1	Remission after antidepressant treatment in major depression	remission,response to antidepressant	unipolar depression	GCST011531	1479247:33:00	33589590	Marshe VS
rs10793705-?	2.00E-06	-	NR	-	-	-	GJA5	Response to antidepressants (pain relief efficacy)	pain measurement,response to antidepressant	chronic pain	GCST012122	2462804:24:00	33685280	Nishizawa D
rs12521425-A	4.00E-07	-	0.715	-	1.12727 unit increase	[1.08-1.17]	PROP1,SUDS3P1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	2966375:27:00	35712048	Pain O
rs113134823-?	8.00E-07	-	0.811	-	0.85138 unit increase	[0.79-0.92]	CEP20,RPL15P20	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	265131:48:00	35712048	Pain O
rs184869221-C	9.00E-07	-	0.977	-	2.65329 unit increase	[2.26-3.04]	ERVK13-1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	44574:20:00	35712048	Pain O
rs75003974-G	9.00E-07	-	0.979	-	1.52653 unit increase	[1.36-1.7]	NCKAP1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	3048640:31:00	35712048	Pain O
rs12649563-G	1.00E-06	-	0.861	-	1.15269 unit increase	[1.1-1.21]	CCSER1,KRT19P6	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	1527526:28:00	35712048	Pain O
rs17364300-C	2.00E-06	-	0.898	-	0.84434 unit increase	[0.77-0.91]	HIVEP3	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	694594:01:00	35712048	Pain O
rs4038474-?	2.00E-06	-	0.742	-	0.89485 unit increase	[0.85-0.94]	DHX8	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	724875:48:00	35712048	Pain O
rs113031044-G	3.00E-06	-	0.978	-	1.40102 unit increase	[1.26-1.54]	LINC01271,RN7SL636P	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	839637:41:00	35712048	Pain O
rs10219012-C	4.00E-06	-	0.796	-	1.11974 unit increase	[1.07-1.17]	WDFY4,ARHGAP22	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	811067:31:00	35712048	Pain O
rs74855424-A	4.00E-06	-	0.97	-	1.36261 unit increase	[1.23-1.49]	RNU6-952P,YAP1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	1705073:08:00	35712048	Pain O
rs2080632-T	4.00E-06	-	0.661	-	1.10849 unit increase	[1.06-1.15]	WSCD1,NLRP1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	98794:31:00	35712048	Pain O
rs11664277-A	5.00E-06	-	0.418	-	1.09735 unit increase	[1.06-1.14]	LIPG,SMUG1P1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	827013:30:00	35712048	Pain O
rs34381219-?	5.00E-06	-	0.665	-	1.11405 unit increase	[1.07-1.16]	RABL3	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	2011428:18:00	35712048	Pain O
rs1426107-C	7.00E-06	-	0.91	-	0.84815 unit increase	[0.78-0.92]	LINC00504,LINC01085	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	238248:36:00	35712048	Pain O
rs116899837-C	7.00E-06	-	0.936	-	1.22691 unit increase	[1.14-1.32]	PRR13P7,RN7SKP231	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	1530379:36:00	35712048	Pain O
rs570948877-?	8.00E-06	-	0.89	-	0.86157 unit increase	[0.8-0.93]	UBE2D3P4,VENTXP2	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	1399034:04:00	35712048	Pain O
rs140712235-?	9.00E-06	-	0.808	-	0.87459 unit increase	[0.82-0.93]	ABCG2	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	1469120:55:00	35712048	Pain O
rs73001560-C	1.00E-05	-	0.881	-	0.86122 unit increase	[0.79-0.93]	HDAC4-AS1,NDUFA10	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244578	3991037:28:00	35712048	Pain O
rs182697269-T	3.00E-06	-	NR	-	0.194 unit decrease	-	OPTC,ATP2B4	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	3393565:36:00	36228427	Yuan J
rs79820597-C	5.00E-06	-	NR	-	0.184 unit decrease	-	EGLN1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	3856399:51:00	36228427	Yuan J
rs745581-C	4.00E-06	-	NR	-	0.057 unit decrease	-	LINC01250,MYT1L	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	45490:54:00	36228427	Yuan J
rs115630863-A	3.00E-06	-	NR	-	0.201 unit decrease	-	GOLGB1	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	2027862:54:00	36228427	Yuan J
rs113728087-G	1.00E-06	-	NR	-	0.079 unit decrease	-	MAP3K13	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	3089627:12:00	36228427	Yuan J
rs74387086-T	9.00E-07	-	NR	-	0.174 unit decrease	-	CXCL13	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	1292793:22:00	36228427	Yuan J
rs10948514-T	9.00E-08	-	NR	-	0.082 unit decrease	-	CYP2AC1P,RHAG	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	826540:40:00	36228427	Yuan J
rs13246263-A	4.00E-06	-	NR	-	0.112 unit decrease	-	POU6F2	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	654754:51:00	36228427	Yuan J
rs943202-A	3.00E-06	-	NR	-	0.079 unit decrease	-	LARP4B,DIP2C	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	13119:39:00	36228427	Yuan J
rs74625347-G	1.00E-06	-	NR	-	0.111 unit decrease	-	BIVM-ERCC5,BIVM	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	1713832:34:00	36228427	Yuan J
rs8017893-G	3.00E-06	-	NR	-	0.145 unit decrease	-	MEG8	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	1681832:08:00	36228427	Yuan J
rs111763479-C	5.00E-06	-	NR	-	0.195 unit decrease	-	GZMM	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	9182:49:00	36228427	Yuan J
rs201267160-AAAT	3.00E-07	-	NR	-	0.117 unit decrease	-	U3,RNU6-27P	Response to antidepressants (symptom improvement) in major depressive disorder	depressive symptom measurement,response to antidepressant	major depressive disorder	GCST90244558	283499:08:00	36228427	Yuan J
rs150175932-?	1.00E-07	-	NR	15.22	-	[3.318-69.804]	DCLK2	Response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003809	2501695:35:00	27622933	Li QS
rs141746753-?	1.00E-06	-	NR	3.2467532	-	[1.84-5.71]	BPNT2,RNU6-13P	Response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003809	948910:34:00	27622933	Li QS
rs73720034-?	1.00E-06	-	NR	1.256	-	[1.142-1.381]	-	Response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003809	2096590:15:00	27622933	Li QS
rs6545694-?	2.00E-06	-	NR	1.096	-	[1.056-1.137]	LINC01122	Response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003809	977015:38:00	27622933	Li QS
rs61519662-?	2.00E-06	-	NR	1.1013216	-	[1.06-1.15]	-	Response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003809	44945:39:00	27622933	Li QS
rs1994321-?	5.00E-07	-	NR	1.1547344	-	[1.09-1.22]	LINC02547,MICAL2	Non-response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003808	201107:06:00	27622933	Li QS
rs113378111-?	7.00E-07	-	NR	1.579	-	[1.303-1.912]	TAF1B,RNU4-73P	Non-response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003808	163135:44:00	27622933	Li QS
rs73788091-?	1.00E-06	-	NR	3.011	-	[2.044-4.437]	FSTL4	Non-response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003808	2223830:17:00	27622933	Li QS
rs9951011-?	2.00E-06	-	NR	1.1806375	-	[1.1-1.26]	-	Non-response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003808	1122792:01:00	27622933	Li QS
rs78620960-?	2.00E-06	-	NR	1.2033695	-	[1.12-1.3]	LINC01720	Non-response to selective serotonin reuptake inhibitors and depression	unipolar depression,response to selective serotonin reuptake inhibitor,mood disorder	-	GCST003808	3180207:09:00	27622933	Li QS
rs190544851-?	3.00E-07	-	NR	14.29	-	[3.555-57.454]	LINC01423,ERG	Non-response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003812	639362:14:00	27622933	Li QS
rs57043326-?	8.00E-07	-	NR	2.65252	-	[1.69-4.17]	C6orf99	Non-response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003812	2648237:41:00	27622933	Li QS
rs12068879-?	1.00E-06	-	NR	2.221	-	[1.667-2.958]	KAZN	Non-response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003812	249332:00:00	27622933	Li QS
rs1322281-?	1.00E-06	-	NR	1.242	-	[1.139-1.354]	PTPRD	Non-response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003812	176383:05:00	27622933	Li QS
rs13418410-?	2.00E-06	-	NR	1.212	-	[1.121-1.311]	RASGRP3,FAM98A	Non-response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003812	559599:12:00	27622933	Li QS
rs34807503-?	5.00E-07	-	NR	1.0905125	-	[1.05-1.13]	SCN8A,SLC4A8	Response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003813	858767:50:00	27622933	Li QS
rs2402960-?	8.00E-07	-	NR	1.098901	-	[1.06-1.14]	MIR182,NRF1	Response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003813	2162772:34:00	27622933	Li QS
rs200312707-?	1.00E-06	-	NR	1.0881393	-	[1.05-1.13]	CDH8	Response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003813	1033878:56:00	27622933	Li QS
rs400736-?	2.00E-06	-	NR	1.0857763	-	[1.05-1.12]	ERRFI1	Response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003813	133638:29:00	27622933	Li QS
rs35265457-?	2.00E-06	-	NR	1.508	-	[1.261-1.803]	NDC1	Response to antidepressants and depression	unipolar depression,mood disorder,response to antidepressant	-	GCST003813	896794:26:00	27622933	Li QS